ArticleBioengineering & translational medicine2026
Combined HER2-targeted mRNA-LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HER2 overexpression is a pivotal oncogenic alteration in NSCLC and is associated with poor prognosis. Existing HER2-targeted therapeutics, including antibody-drug conjugates, have limited anticancer efficacy and prominent systemic toxicity, whereas radiotherapy-mediated tumor immunosuppression further hinders therapeutic outcomes. This study aimed to construct a HER2-targeted mRNA vaccine delivered by lipid nanoparticles (LNPs), designated HER2-mRNA-LNP, and to explore its standalone or combined anti-tumor effects alone or in combination with radiotherapy (RT) in HER2-overexpressing NSCLC xenografts, as well as the underlying immune regulatory mechanisms. We first prepared the HER2-mRNA-LNP vaccine and constructed HER2-overexpressing Lewis lung carcinoma (LLC) cell line (HER2-LLC) to establish matching tumor-bearing xenograft mice. Tumor-bearing mice were divided into four groups: LNP control, HER2-mRNA-LNP, RT, and HER2-mRNA-LNP + RT (combination). Prophylactic and therapeutic effects were assessed by measuring tumor volume and weight, performing CCK-8 cytotoxicity assays, immunohistochemistry (HER2, Ki67), and flow cytometry for immune cell profiling. Our results demonstrated that HER2-mRNA-LNP significantly reduced tumor volume and weight compared with LNP controls and this suppression was further enhanced when combined with RT. Expression of HER2 and Ki67 decreased in both the HER2-mRNA-LNP and combination groups. HER2-mRNA-LNP increased the proportions of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.